Señales en vivo de PBYI | Maximiza tus Ganancias con Getagraph.com

COMPRAR 115865 min ago

@ $7.35

Emitido: 14 feb 2024 @ 15:31

Retorno: -33.88%

Señal anterior: feb 13 - 15:35

Señal anterior: Vender

Retorno: 18.17 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally...

Stats
Volumen de hoy	388 031
Volumen promedio	585 132
Capitalización de mercado	234.29M
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $-0.220 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	10.80
ATR14	$0.00900 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Auerbach Alan H	Buy	6 577	Common Stock
2024-03-15	Auerbach Alan H	Buy	9 047	Stock Option (Right to Buy)
2024-02-12	Wong Alvin F	Buy	43 307	Common Stock
2024-02-12	Wong Alvin F	Buy	59 946	Stock Option (Right to Buy)
2024-02-12	Nougues Maximo F	Buy	43 307	Common Stock

INSIDER POWER
69.70
Last 99 transactions
Buy: 2 879 886 \| Sell: 561 464

Volumen Correlación

Largo: 0.14 (neutral)

Corto: -0.68 (moderate negative)

Signal:(32.798) Neutral

Puma Biotechnology Inc Correlación

10 Correlaciones Más Positivas
FAT	0.831
OHAA	0.828
ISEM	0.815

10 Correlaciones Más Negativas
RMRM	-0.839

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Puma Biotechnology Inc Correlación - Moneda/Commodity

0.50
( neutral )

0.48
( neutral )

0.00
( neutral )

0.48
( neutral )

-0.45
( neutral )

Puma Biotechnology Inc Finanzas

Annual	2023
Ingresos:	$235.64M
Beneficio Bruto:	$172.96M (73.40 %)
EPS:	$0.460

FY	2023
Ingresos:	$235.64M
Beneficio Bruto:	$172.96M (73.40 %)
EPS:	$0.460

FY	2022
Ingresos:	$228.00M
Beneficio Bruto:	$172.90M (75.83 %)
EPS:	$0.0204

FY	2021
Ingresos:	$253.16M
Beneficio Bruto:	$189.45M (74.84 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.